Primary carcinoma of the Fallopian tubes is a very rare, but highly aggressive tumour. Worldwide, little more than 1,500 cases have been published (Pfleiderer, 1984) . Renaud described the disease as early as 1847 (Renaud & Ricci, 1945) , and Rokitansky in 1861, yet Orthmann (1886 Orthmann ( , 1888 was the first to mention carcinoma of the Fallopian tube as a pathologic entity in 1866. The most extensive documentation on carcinoma of the Fallopian tube was published by Niirnberger in 1932.
The incidence of carcinoma of the Fallopian tube among the neoplasms of the female genital tract varies between 0.15 and 1.8% (Hanton et al., 1966; Sedlis, 1969; Dodson et al., 1970; Engeler et al., 1981) . A Danish study reports an incidence of 0.29 out of 100,000 women (Pfeiffer et al., 1989) . From 1980 onwards, cancer of the tuba uterina has been requested by the Cancer Registry of the Austrian Central Statistical Office. During the period from 1980 to 1990, a total of 213 cases was reported in Austria; the annual distribution is given in Table I. There is a peak incidence in higher age groups. On average the disease occurs within the sixth decennium of life (Engeler (Bohme et al., 1992; Kubista & Kubka, 1977) .
The recurring discharge, a serous fluid amber to reddish in colour, is pathognomonic. It occurs extremely rarely and therefore is often misinterpreted (Niirnberger, 1932;  Sedlis, 1969; Benedet & White, 1981) . For these reasons, primary carcinoma of the Fallopian tube is in fact diagnosed intraoperatively or most often histologically (Jones, 1965; Eddy et al., 1984 A modified FIGO-classification was applied to stage tumours (Table II) . Histologic evaluation and grading followed the criteria of Hu et al. (1950) : the main tumour is located in the tube, arising from tubal epithelium. There is evidence of a transitional zone between epithelium and malignant epitheloid cells. Ovaries and uterus respectively exhibit normal epithelial cover or a lesser degree of tumour growth than the tubes.
The participating departments provided the study centre with histologic specimens which were evaluated by an independent pathologist (A.R.) for grading and histologic type.
Furthermore the presence of ascites and the size of a residual tumour after surgical removal of the cancer were evaluated for their prognostic impact.
The results expressed as percentage were subjected to a chi-square-test. Survival curves were obtained by the KaplanMeier method, and the median survival times compared by the Mantel-Cox log-rank test (Kaplan & Meier, 1958; Mantel, 1986; Cox, 1972) . Values of P<0.05 were considered to be statistically significant.
The Cox regression method was used in multivariate survival analysis to identify a combination of factors that significantly impacted on survival (Cox, 1972) . Independent variables were identified as those factors chosen which had reached statistical significance or at least a statistical trend in the univariate analysis.
Wherever feasible, hazard plots were performed to assess the appropriateness of the proportional hazards assumption that underlies the Cox regression model. Log-likelihood ratio test was used to determine the significance of factor combinations.
Results
A total of 115 cases of primary cancer of the Fallopian tube were included into the study. The mean age of the patients was about 62.5 years, ranging from 37.3 to 82.0 years. In 47 (Table IV) .
Patients were treated postoperatively either by irradiation or chemotherapy. High-voltage radiotherapy was performed on 40 (34.8%) women at a dosage of 4,500 to 5,000 rad to standard pelvic fields. Forty-nine (42.6%) patients received chemotherapy, the scheme varying from department to department; in 13 cases the PAC-regime (Morris, 1990 ) (cisplatin, endoxan and doxirubicin) was given; 14 patients received cisplatin as single agent; five women were treated with carboplatin; four patients received Epirubicin and Endoxan in combination; 13 women were treated with a combination of cisplatin and methotrexate.
Twenty-six (22.6%) women did not receive any adjuvant therapy because their tumours were either stage Ia (n = 10) or they had a performance status III-IV according to WHO. In the latter cases all tumours were in stage IV (n = 16).
The clinical symptoms in our patients corresponded on the whole to those described in the literature, e.g. abnormal vaginal bleeding, whitish-clear discharge, undefined abdominal pain or increase in abdominal circumference.
Median survival time for all stages was 30.7 months, with an observation period of at least one and maximally 144 months. Patients with tumous in stages I and II (n = 67) had a median survival time of 55.7 months (min = 1; max = 144). Median survival in stages III and IV (n = 48) was about 20.8 months (min = 1; max = 77).
The 5-year survival in stages I and II was 50.8% compared to about 13.6% in stages III and IV (Figure 1) .
Patients with tumour of grading I or II showed a better survival compared to tumour with grading III although this failed to reach statistical significance (P= 0.09) (Figure 2) .
Patients with papillary cancer had median survival of 42.7 months, compared with 29.1 months in serous, 11.4 months Since ascites is accepted as a well established prognostic factor for ovarian cancer, its influence on survival was analysed, but did not reveal any impact on the outcome (P = 0.2), probably due to the rare incidence of ascites on the whole (21.7%) in stages III and IV only (Anonymous, 1981; Berek et al., 1983) .
The presence of residual tumour -also a prognosticator for ovarian cancer -was also detected in stages III and IV only (Anonymous, 1981; Berek et al., 1983) . Even in advanced disease patients with residual tumour less than 2 cm had a significantly better outcome compared to women with a larger remaining mass (P = 0.03) (Figure 3) .
On multivariate analysis, the most powerful predictor of outcome in women with tubarian cancer was the FIGO-stage (the population dichotomised for stage I + II vs III + IV) (P = 0.003). The only factor that added significantly to the predictive power of the FIGO-stage was the residual tumour (<2 cm vs >2 cm) (P = 0.02). Histologic grading failed to reach any significance (P = 0.344).
Discussion
Primary cancer of the Fallopian tube is so rare that data from single institutions cannot lead to any substantial conclusions regarding therapy or prognosis. Worldwide, about 1,500 cases have been reported in the literature up to now, with hardly more than a 100 cases per study (Table V) .
A retrospective evaluation of multi-centre data was undertaken covering a period of 12 years. Our results, as fo age, and distribution of stages, are comparable to those o0 other authors (Pfleiderer, 1984; Bohme et al., 1992; Kubista & Kupka, 1977; Jones, 1965; Denham & MacLennan, 1984; McMurray et al., 1986) .
In the past, several authors tried to describe factors predisposing for a cancer of the Fallopian tube, by analysing factors like menarche, menopause, parity and race (Engeler Pfeiffer et al., 1989; Bohme et al., 1992; Kubista & Kupka, 1977; Eddy et al., 1984) . The results, in most cases obtained from small patient-populations, were too heterogenous to be reliable. Neither did studies on symptoms contribute any further information for early diagnosis of this disease (B6hme et al., 1992; Kubista & Kupka, 1977; Benedet & White, 1981; Schiller & Silverberg, 1971; Roberts & Lifshitz, 1982) .
Even though cancer of the Fallopian tube and of the ovaries are histologically graded in one class, due to the same origin from one germinal epithelium (Pfleiderer, 1984; Bohme et al., 1992; Kubista & Kupka, 1977) , there exist differences between the two entities: first, in most cases cancer of the Fallopian tube is diagnosed at an earlier stage than the ovarian cancer and patients are able to seek medical attention earlier. Another difference between tubal and ovarian cancer is that distant metastasis is relatively more important as site of failure than in ovarian cancer.
McMurray reports that almost half of the recurrences presented outside the peritoneal cavity, although usually in association with intraperitoneal metastases (McMurray, 1986) .
The reason for the earlier diagnosis of the carcinoma of the Fallopian tube may be due to the painful tension in the tubes, and to the abnormal discharge of serous fluid which occurs frequently. An occlusion of the abdominal ostium of the uterine tube in some patients may be the cause for these phenomena (Benedet & White, 1981 ; Denham & McLennan, 1984) .
It might be possible that this could lead to a delay in lymphogenous and/or continuous growth of the tumour. This could explain the higher incidence of prognostically more favourable, early stages compared to ovarian cancer. Green and Scully in 1962 reported on five patients who survived in their series of 18 cases, and where the lateral ostium tubae was occluded.
Histologically, the tumour is presented as adenocarcinoma of various types (Pfleiderer, 1984; Eddy et al., 1984) . In our collective, papillary (48.6%) and serous (16.5%) adenomatous structures were predominant, while in relation to that other manifestations like solid, medullary, and mucinous structures were less frequent.
Highly differentiated cells were found in 46.1% of the patients, and such of medium and low degree of differentiation were present in only 33.9% and 20.0% of the cases respectively. These results are comparable to those of McMurray (1986) ; (GI = 39%, G2 = 20%, G3 = 43%) and other authors (Pfeiffer, 1989; Benedet & White, 1981; Denham & McLennan, 1984) .
On the whole, better differentiated tumours, showed a trend to a more favourable outcome, compared with G3 tumours (Figure 2 ). However, this influence did not reach significance, neither in univariate nor multivariate analysis.
Contrary to this finding, a residual tumour mass less than 2 cm in patients with advanced disease (stage III and IV) had a positive independent impact on survival compared to patients with a bigger residual tumour mass (Figure 3) .
On the other hand ascites -a strong prognosticator in ovarian cancer (Anonymous, 1981; Berek et al., 1983) (Table IV) . Patients with stage III and IV were also analysed as one group with advanced disease.
Statistical evaluation showed a significantly (P = 0.0001) higher number of cases in stages I and II (n = 67 or 58.3%) than in stages III and IV (n = 48 or 41.7%) compared to ovarian cancer (Sevelda et al., 1991) .
The 5-year survival rate of all our patients was 36.5%. In stages I and II 50.8% compared to 13.6% in stages III and IV. This is comparable to that reported by other authors (Bohme et On the whole, staging according to the modified FIGOsystem had the strongest influence on survival, univariate as well as multivariate analysis.
In the majority of the cases, the above mentioned early diagnosis allows a radical operative stabilisation (Engeler et al., 1981) . Ninety-five women in our series underwent radical hysterectomy including the adnexa, and/or total resection of the omentum, or lymphadenectomy respectively. Surgeons succeeded in complete tumour removal in 82 cases (71.3%); in 33 cases, which were all in stages III and IV, some residual tumour had to be left.
As better outcome is invariably linked to early diagnosis, the advantage of early detection should not be lost by less radical surgery. Surgical intervention should be as complete as possible, corresponding to the guidelines which are applied in cases of ovarian cancer.
